In patients with HIV, a diabetes drug may have benefits beyond lowering blood sugar. A new study from researchers at Washington University School of Medicine in St. Louis suggests the drug may prevent cardiovascular problems ...
May 14, 2015
0
88
Treatment with PCSK9 antibodies reduces mortality and produces profound reductions in LDL-cholesterol and lipoprotein in patients with dyslipidemia. The results of this systematic review and meta-analysis are being published ...
Apr 27, 2015
0
6
Among patients receiving antithrombotic therapy (to prevent the formation of blood clots) after a heart attack, the use of nonsteroidal anti-inflammatory drugs (NSAIDs) was associated with an increased risk of bleeding and ...
Feb 24, 2015
0
5
(HealthDay)—Use of specific nonsteroidal anti-inflammatory drugs (NSAIDs), diclofenac and aceclofenac, is associated with increased risk of nonfatal ischemic stroke, according to a study published online Jan. 22 in the ...
Feb 12, 2015
0
5
The Food and Drug Administration said Wednesday it will require makers of heart-zapping defibrillators to submit more data on the emergency devices after years of recalls and manufacturing problems.
Jan 28, 2015
0
2
Victoria University of Wellington research has identified reasons why a significant portion of heart attack patients do not respond to commonly used treatments.
Dec 8, 2014
0
0
(HealthDay)—Patients' preferences for outcomes of anticoagulation therapy vary and are affected by previous stroke or myocardial infarction experience, according to a study published online Nov. 11 in Circulation: Cardiovascular ...
Nov 12, 2014
0
0
Evolocumab, an injected form of a new class of drugs called PCSK9 inhibitors[1], is highly effective at reducing low-density lipoprotein (LDL) or "bad cholesterol" levels with few side effects in people with familial hypercholesterolaemia ...
Oct 2, 2014
0
0
(HealthDay)—Movantik (naloxegol) has been approved by the U.S. Food and Drug Administration to treat opioid-induced constipation, the agency said Tuesday.
Sep 16, 2014
0
0
Lowering the drug threshold for high blood pressure has exposed millions of low-risk people around the world to drug treatment of uncertain benefit at huge cost to health systems, warn US experts in BMJ today.
Sep 14, 2014
0
0
